-
1.发明申请公开(公告)号：US20190262306A1
公开(公告)日：2019-08-29
申请号：US16342610
申请日：2017-10-18
申请人： lnstitut National de Ia Sante et de Ia Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Sorbonne Universite , Universite de Poitiers , Centre Hospitalier Universitaire de Poitiers
IPC分类号： A61K31/352 , A61K45/06 , A61P27/02 , A61P25/00
摘要： The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
-
2.发明申请公开(公告)号：US20220096426A1
公开(公告)日：2022-03-31
申请号：US17547501
申请日：2021-12-10
申请人： Institut National de Ia Sante et de Ia Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Sorbonne Universite , Universite de Poitiers , Centre Hospitalier Universitaire de Poitiers
IPC分类号： A61K31/352 , A61P27/02 , A61P25/00 , A61K45/06 , C07D311/20 , C07D311/54
摘要： The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
-
3.发明授权公开(公告)号：US11224586B2
公开(公告)日：2022-01-18
申请号：US16342610
申请日：2017-10-18
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Sorbonne Universite , Universite de Poitiers , Centre Hospitalier Universitaire de Poitiers
IPC分类号： A61K31/352 , A61K45/06 , A61P27/02 , A61P25/00 , C07D311/20 , C07D311/54
摘要： The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
-
4.发明授权公开(公告)号：US11819492B2
公开(公告)日：2023-11-21
申请号：US17547501
申请日：2021-12-10
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Sorbonne Universite , Universite de Poitiers , Centre Hospitalier Universitaire de Poitiers
IPC分类号： A61K31/352 , A61P27/02 , A61P25/00 , A61K45/06 , C07D311/20 , C07D311/54
CPC分类号： A61K31/352 , A61K45/06 , A61P25/00 , A61P27/02 , C07D311/20 , C07D311/54
摘要： The present invention relates to a compound of the following general formula (I):
or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
-
-
-
搜索结果
4 条记录 (耗时 0.034 秒)
